WuXi Biologics (Cayman)MEX:2269N 99 Altman Z-Score is 8.24 as of Jun. 28, 2026, which is 47% below its 10-year median of 15.54. GuruFocus rates MEX:2269N with a GF Score™ of 99/100 and a GF Value™ of MXN72.14. The stock has 3 warning signs investors should review. Among 934 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 74.84% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 8.47 is strong.
WuXi Biologics (Cayman) has a Altman Z-Score of 8.24, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for WuXi Biologics (Cayman)'s Altman Z-Score or its related term are showing as below:
MEX:2269N'
s Altman Z-Score Range Over the Past 10 Years
Min: 4.87 Med: 15.54 Max: 32.44
Current: 8.47
During the past 12 years, WuXi Biologics (Cayman)'s highest Altman Z-Score was 32.44. The lowest was 4.87. And the median was 15.54.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:2269N vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Altman Z-Score distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
WuXi Biologics (Cayman) (MEX:2269N) has a Altman Z-Score of 8.24 as of Jun. 28, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on WuXi Biologics (Cayman) and its competitors. This is 47% below median its historical median of 15.54. Over the past decade, WuXi Biologics (Cayman)'s Altman Z-Score has ranged from 4.87 to 32.44. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #235 out of 934 companies in the Biotechnology industry, placing it in the top 25.2%.
Is WuXi Biologics (Cayman)'s Altman Z-Score too high?
WuXi Biologics (Cayman)'s current Altman Z-Score of 8.24 is 47% below median its 10-year median of 15.54. Over the past 10 years, this metric has ranged from a low of 4.87 to a high of 32.44. The Biotechnology industry median Altman Z-Score is 2.63. WuXi Biologics (Cayman)'s value of 8.24 is 213.9% above this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #235 out of 934 companies in the Biotechnology industry, which is above the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #235 out of 934 companies for Altman Z-Score. This puts WuXi Biologics (Cayman) in the upper half of its industry. The industry median Altman Z-Score is 2.63. WuXi Biologics (Cayman)'s value of 8.24 is 213.9% above this benchmark. Historically, WuXi Biologics (Cayman)'s own Altman Z-Score has ranged from 4.87 to 32.44 over the past decade. While the company's 10-year median is 15.54 vs. the industry median of 2.63, WuXi Biologics (Cayman) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.63, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Altman Z-Score of 8.24 is 213.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Altman Z-Score is 8.24, which is 47% below median its own 10-year median of 15.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current Altman Z-Score of 8.24. The stock's GF Value™ is MXN72.14, compared to a current price of MXN62.53 — trading 13.3% below its estimated fair value. The current Altman Z-Score is 8.24, which is 47% below median its 10-year median of 15.54 and 213.9% above the Biotechnology industry median of 2.63. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current Altman Z-Score is 8.24 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of MXN62.53 is trading 13.3% below its estimated GF Value™ of MXN72.14.
Key valuation signals for MEX:2269N:
Altman Z-Score: 8.24 (47% below median its 10-year median of 15.54)
GF Value™: MXN72.14 vs. price of MXN62.53 (13.3% below fair value)
Industry Position: 213.9% above the Biotechnology median (#235 of 934)
No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score
Get the complete analysis for MEX:2269N
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2269N has been successfully added to your 
